Reduced tumor growth in EP2 knockout mice is related to signaling pathways favoring an increased local anti‑tumor immunity in the tumor stroma

Khan,Maria; Engström,Cecilia; Fagman,Johan Bourghardt; Smedh,Ulrika; Lundholm,Kent; Iresjö,Britt-Marie

doi:10.3892/or.2022.8329

Reduced tumor growth in EP2 knockout mice is related to signaling pathways favoring an increased local anti‑tumor immunity in the tumor stroma

Authors:
- Maria Khan
- Cecilia Engström
- Johan Bourghardt Fagman
- Ulrika Smedh
- Kent Lundholm
- Britt-Marie Iresjö
View Affiliations

Affiliations: Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden
Published online on: May 11, 2022 https://doi.org/10.3892/or.2022.8329
Article Number: 118
Copyright: © Khan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory signaling through prostaglandin E2 receptor subtype 2 (EP2) is associated with malignant tumor growth in both experimental models and cancer patients. Thus, the absence of EP2 receptors in host tissues appears to reduce tumor growth and systemic inflammation by inducing major alterations in gene expression levels across tumor tissue compartments. However, it is not yet well‑established how signaling pathways in tumor tissue relate to simultaneous signaling alterations in the surrounding tumor‑stroma, at conditions of reduced disease progression due to decreased host inflammation. In the present study, wild‑type tumor cells, producing high levels of prostaglandin E2 (MCG 101 cells, EP2^+/+), were inoculated into EP2 knockout (EP2^‑/‑) and EP2 wild‑type (EP2^+/+) mice. Solid tumors were dissected into tumor‑ and tumor‑stroma tissue compartments for RNA expression microarray screening, followed by metabolic pathway analyses. Immunohistochemistry was used to confirm adequate dissections of tissue compartments, and to assess cell proliferation (Ki‑67), prostaglandin enzymes (cyclooxygenase 2) and immunity biomarkers (CD4 and CD8) at the protein level. Microarray analyses revealed statistically significant alterations in gene expression in the tumor‑stroma compartment, while significantly less pathway alterations occurred in the tumor tissue compartment. The host knockout of EP2 receptors led to a significant downregulation of cell cycle regulatory factors in the tumor‑stroma compartment, while interferon γ‑related pathways, chemokine signaling pathways and anti‑tumor chemokines [chemokine (C‑X‑C motif) ligand 9 and 10] were upregulated in the tumor compartment. Thus, such gene alterations were likely related to reduced tumor growth in EP2‑deficient hosts. On the whole, pathway analyses of both tumor‑ and tumor‑stroma compartments suggested that absence of host EP2 receptor signaling reduces ‘remodeling’ of tumor microenvironments and increase local immunity, probably by decreased productions of stimulating growth factors, perhaps similar to well‑recognized physiological observations in wound healing.

View Figures

View References

1	Wang D and DuBois RN: Role of prostanoids in gastrointestinal cancer. J Clin Invest. 128:2732–2742. 2018. View Article : Google Scholar
2	Lundholm K, Gelin J, Hyltander A, Lönnroth C, Sandström R, Svaninger G, Körner U, Gülich M, Kärrefors I, Norli B, et al: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54:5602–5606. 1994.PubMed/NCBI
3	Aoki T and Narumiya S: Prostaglandin E₂-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment. Inflamm Regen. 37:42017. View Article : Google Scholar : PubMed/NCBI
4	Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lönnroth C and Lundholm K: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 121:232–240. 2007. View Article : Google Scholar : PubMed/NCBI
5	Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lönnroth C and Lundholm K: Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol. 46:1107–1112. 2007. View Article : Google Scholar
6	Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 7:1048–1051. 2001. View Article : Google Scholar : PubMed/NCBI
7	Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, Yu JJ, Yu Y, Shi Z and Jiang J: Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. Br J Pharmacol. 176:1680–1699. 2019. View Article : Google Scholar
8	Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP and Breyer RM: Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 111:727–735. 2003. View Article : Google Scholar
9	Iresjö BM, Wang W, Nilsberth C, Andersson M, Lönnroth C and Smedh U: Food intake, tumor growth, and weight loss in EP2 receptor subtype knockout mice bearing PGE2-producing tumors. Physiol Rep. 3:e124412015. View Article : Google Scholar
10	Asting AG, Iresjö BM, Nilsberth C, Smedh U and Lundholm K: Host knockout of E-prostanoid 2 receptors reduces tumor growth and causes major alterations of gene expression in prostaglandin E₂-producing tumors. Oncol Lett. 13:476–482. 2017. View Article : Google Scholar
11	Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD and Breyer RM: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 5:217–220. 1999. View Article : Google Scholar : PubMed/NCBI
12	Lonnroth C, Svaninger G, Gelin J, Cahlin C, Iresjo B, Cvetkovska E, Edstrom S, Andersson M, Svanberg E and Lundholm K: Effects related to indomethacin prolonged survival and decreased tumor-growth in a mouse-tumor model with cytokine dependent cancer cachexia. Int J Oncol. 7:1405–1413. 1995.
13	Lundholm K, Edström S, Karlberg I, Ekman L and Scherstén T: Relationship of food intake, body composition, and tumor growth to host metabolism in nongrowing mice with sarcoma. Cancer Res. 40:2516–2522. 1980.PubMed/NCBI
14	Axelsson H, Lönnroth C, Andersson M and Lundholm K: Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo. Int J Oncol. 37:1143–1152. 2010.
15	Andersson C, Gelin J, Iresjö BM and Lundholm K: Acute-phase proteins in response to tumor growth. J Surg Res. 55:607–614. 1993. View Article : Google Scholar : PubMed/NCBI
16	Wang W, Andersson M, Lönnroth C, Svanberg E and Lundholm K: Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Clin Cancer Res. 24:99–107. 2005.PubMed/NCBI
17	Svaninger G, Lundberg PA and Lundholm K: Thyroid hormones and experimental cancer cachexia. J Natl Cancer Inst. 77:555–561. 1986.
18	McKinney EF, Cuthbertson I, Harris KM, Smilek DE, Connor C, Manferrari G, Carr EJ, Zamvil SS and Smith KGC: A CD8⁺ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis. Nat Commun. 12:6352021. View Article : Google Scholar : PubMed/NCBI
19	Hansen T: Inhibition of T-cell responses by CD4 on an antigen-presenting cell. APMIS. 114:32–38. 2006. View Article : Google Scholar : PubMed/NCBI
20	Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K and Lundholm K: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 8:52008.
21	Woodward DF, Jones RL and Narumiya S: International union of basic and clinical pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 63:471–538. 2011. View Article : Google Scholar : PubMed/NCBI
22	Axelsson H, Lönnroth C, Wang W, Svanberg E and Lundholm K: Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice. Angiogenesis. 8:339–348. 2005. View Article : Google Scholar : PubMed/NCBI
23	Mizuno R, Kawada K and Sakai Y: Prostaglandin E2/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci. 20:62542019. View Article : Google Scholar
24	Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H and Lenz HJ: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation-a target for novel cancer therapy. Cancer Treat Rev. 63:40–47. 2018. View Article : Google Scholar : PubMed/NCBI
25	Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M and Avril S: CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer. 115:553–563. 2016. View Article : Google Scholar : PubMed/NCBI
26	Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M and Schmitt M: Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res. 14:R302012. View Article : Google Scholar : PubMed/NCBI
27	Kistner L, Doll D, Holtorf A, Nitsche U and Janssen KP: Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. Oncotarget. 8:89998–90012. 2017. View Article : Google Scholar
28	Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE and Luster AD: IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 168:3195–3204. 2002. View Article : Google Scholar
29	Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH and Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 182:155–162. 1995. View Article : Google Scholar : PubMed/NCBI
30	Hartner JC, Walkley CR, Lu J and Orkin SH: ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol. 10:109–115. 2009. View Article : Google Scholar
31	Domingo-Gil E and Esteban M: Role of mitochondria in apoptosis induced by the 2-5A system and mechanisms involved. Apoptosis. 11:725–738. 2006. View Article : Google Scholar : PubMed/NCBI
32	Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, Hsu YT, Silverman RH and Youle RJ: The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ. 5:313–320. 1998. View Article : Google Scholar : PubMed/NCBI
33	Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 9:1–9. 2003.PubMed/NCBI
34	Houseknecht KL, Cole BM and Steele PJ: Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: A review. Domest Anim Endocrinol. 22:1–23. 2002. View Article : Google Scholar
35	Han S, Inoue H, Flowers LC and Sidell N: Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res. 9:4627–4635. 2003.PubMed/NCBI
36	James SY, Lin F, Kolluri SK, Dawson MI and Zhang XK: Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res. 63:3531–3538. 2003.PubMed/NCBI
37	Han S and Roman J: Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun. 314:1093–1099. 2004. View Article : Google Scholar : PubMed/NCBI